U.S. HMO Industry Faces Challenges and Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Source: NASDAQ.COM
- Rising Medical Costs: U.S. health insurers are experiencing increased medical expenses due to the resumption of deferred care and heightened demand for chronic disease management, leading to a rise in insurance claims and pressure on profit margins.
- Regulatory Uncertainty: New legislation may tighten Medicaid eligibility and reduce ACA enrollment, impacting insurers' membership and reimbursements, which forces a shift towards commercial insurance products to enhance profitability.
- Healthcare Workforce Shortage: The ongoing shortage of nurses and healthcare professionals is straining hospital operations, affecting HMOs' ability to deliver high-quality care, which could lead to customer attrition.
- M&A Strategy: HMO companies are pursuing mergers and acquisitions to expand market share and enhance competitiveness, with expected interest rate declines in 2026 likely to fuel further M&A activity, driving industry consolidation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 270.590
Low
330.00
Averages
397.82
High
444.00
Current: 270.590
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, and social well-being. Optum Health delivers primary, specialty and surgical care and helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Berkshire Increases Stake in UnitedHealth Amid Revenue Decline
- Berkshire's Stake Increase: In August 2025, Berkshire Hathaway purchased over 5 million shares of UnitedHealth (UNH) for approximately $1.6 billion, making it one of its largest equity holdings at the time, despite the insurer facing mounting regulatory scrutiny and rising healthcare costs.
- Revenue Outlook Decline: UnitedHealth now expects its first annual revenue decline in over 30 years, with 2026 revenue projected just above $439 billion, representing a 2% decrease from 2025 levels, which negatively impacts the company's long-term growth prospects.
- AI Strategy Potential: Despite recent challenges, Bernstein SocGen maintains an 'Outperform' rating with a $405 price target, highlighting UnitedHealth's expanding AI strategy as a potential long-term competitive advantage, particularly in reducing operating costs and gaining market share.
- Market Sentiment Shift: Retail investor sentiment for UnitedHealth has shifted from neutral to bullish amid extremely high message volume, indicating a growing optimism about its future performance, even as the stock has lost nearly half its value over the past year.
See More
Raymond James Upgrades UnitedHealth Group Stock Rating
- Rating Upgrade: Analyst John Ransom from Raymond James upgraded UnitedHealth Group (UNH) from Market Perform to Outperform, setting a new price target of $330 per share, projecting EPS for 2027 and 2028 to exceed consensus estimates by 7.5% and 8%, respectively.
- Cost Improvement Expectations: A modest 20 basis point improvement in general and administrative expenses is anticipated for 2027 and 2028, driven by potential AI initiatives and margin enhancements in the health services segment, Optum Health, thereby boosting profitability.
- Valuation Analysis: UnitedHealth trades at 12.7x and 10.6x its non-GAAP EPS estimates for 2027 and 2028, which aligns with historical multiples of peers but represents a significant discount to its own historical multiple of 20x, indicating a potential investment opportunity.
- Earnings Upside Potential: The analyst highlighted that the potential upside to earnings estimates over the next few years stems from 1) announced and potential AI initiatives aimed at reducing G&A/revenue, and 2) margin improvements in Optum Health through better risk margins, lower G&A, and higher fee-for-service margins.
See More
Latest Wall Street Ratings Overview
- Boeing Rating: Wells Fargo initiates coverage of Boeing with a Buy rating, forecasting a significant recovery in free cash flow as production normalizes, setting a price target of $250 based on a 20x FCF multiple on its 2028 forecast, indicating strong confidence in future growth.
- Disney Upgrade: Raymond James upgrades Disney from Market Perform to Outperform with a price target of $115, viewing the current macro backdrop and international visitation challenges as an attractive investment opportunity, reflecting optimism about its valuation.
- Microsoft Buy Rating: Benchmark initiates Microsoft with a Buy rating and a price target of $450, describing it as a juggernaut in artificial intelligence, leveraging its comprehensive portfolio of digital applications and cloud services to drive enterprise and consumer transformation, showcasing its strong market position.
- Algonquin Power Rating: Barclays initiates coverage of Algonquin Power & Utilities with an Overweight rating, citing the company's undervaluation and strong turnaround potential, indicating market confidence in its future performance.
See More
Private Sector Adds 62,000 Jobs in March, Exceeding Expectations
- Job Growth Overview: Private sector employment increased by 62,000 in March, down 4,000 from February's revised total of 66,000 but exceeding the Dow Jones estimate of 39,000, indicating resilience in economic recovery.
- Sector Contribution Analysis: The education and health services sector contributed 58,000 jobs, while construction added 30,000, highlighting the critical role of the health services industry in transforming the labor market.
- Small Business Dominance: Businesses with fewer than 50 employees added 85,000 jobs, while medium-sized firms lost 20,000, indicating a shift towards small businesses leading the recovery, potentially due to inflation impacts and the need for multiple jobs.
- Wage Growth Trends: Wage growth for those remaining in their jobs held steady at 4.5%, while job changers saw a 6.6% increase, up 0.3 percentage points from February, reflecting tightening competition in the labor market.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
Schwab U.S. Dividend Equity ETF Reconstitution Boosts Healthcare Allocation
- Annual Reconstitution Update: The Schwab U.S. Dividend Equity ETF has optimized its portfolio through the deletion of 22 stocks and the addition of 25 new stocks in its latest annual reconstitution, ensuring it holds the top 100 high-yield dividend stocks and enhancing overall portfolio quality.
- Increased Healthcare Allocation: Following the reconstitution, the allocation to the healthcare sector has risen from 15.4% to 18.9%, with UnitedHealth and Abbott Laboratories joining the top ten holdings at 4% and 3.95% respectively, thereby strengthening the fund's investment in the healthcare sector.
- Dividend Growth Potential: While the overall dividend yield of the ETF remains at 3.4% post-reconstitution, the new holdings boast a higher average five-year dividend growth rate of 9.4%, which is expected to generate greater long-term income for investors, enhancing the fund's appeal.
- Strong Dividend Track Record: Both UnitedHealth and Abbott Laboratories have impressive dividend growth records, with the former increasing dividends by 52% over the past five years and the latter by 40%, providing investors with a stable income source and further solidifying the ETF's investment value.
See More
Berkshire Increases Stake in UnitedHealth Amid Revenue Decline
- Berkshire's Stake Increase: In August 2025, Berkshire Hathaway purchased over 5 million shares of UnitedHealth (UNH) for approximately $1.6 billion, making it one of its largest equity holdings at the time, despite the insurer facing mounting regulatory scrutiny and rising healthcare costs.
- Revenue Outlook Decline: UnitedHealth now expects its first annual revenue decline in over 30 years, with 2026 revenue projected just above $439 billion, representing a 2% decrease from 2025 levels, which negatively impacts the company's long-term growth prospects.
- AI Strategy Potential: Despite recent challenges, Bernstein SocGen maintains an 'Outperform' rating with a $405 price target, highlighting UnitedHealth's expanding AI strategy as a potential long-term competitive advantage, particularly in reducing operating costs and gaining market share.
- Market Sentiment Shift: Retail investor sentiment for UnitedHealth has shifted from neutral to bullish amid extremely high message volume, indicating a growing optimism about its future performance, even as the stock has lost nearly half its value over the past year.
See More
Raymond James Upgrades UnitedHealth Group Stock Rating
- Rating Upgrade: Analyst John Ransom from Raymond James upgraded UnitedHealth Group (UNH) from Market Perform to Outperform, setting a new price target of $330 per share, projecting EPS for 2027 and 2028 to exceed consensus estimates by 7.5% and 8%, respectively.
- Cost Improvement Expectations: A modest 20 basis point improvement in general and administrative expenses is anticipated for 2027 and 2028, driven by potential AI initiatives and margin enhancements in the health services segment, Optum Health, thereby boosting profitability.
- Valuation Analysis: UnitedHealth trades at 12.7x and 10.6x its non-GAAP EPS estimates for 2027 and 2028, which aligns with historical multiples of peers but represents a significant discount to its own historical multiple of 20x, indicating a potential investment opportunity.
- Earnings Upside Potential: The analyst highlighted that the potential upside to earnings estimates over the next few years stems from 1) announced and potential AI initiatives aimed at reducing G&A/revenue, and 2) margin improvements in Optum Health through better risk margins, lower G&A, and higher fee-for-service margins.
See More
Latest Wall Street Ratings Overview
- Boeing Rating: Wells Fargo initiates coverage of Boeing with a Buy rating, forecasting a significant recovery in free cash flow as production normalizes, setting a price target of $250 based on a 20x FCF multiple on its 2028 forecast, indicating strong confidence in future growth.
- Disney Upgrade: Raymond James upgrades Disney from Market Perform to Outperform with a price target of $115, viewing the current macro backdrop and international visitation challenges as an attractive investment opportunity, reflecting optimism about its valuation.
- Microsoft Buy Rating: Benchmark initiates Microsoft with a Buy rating and a price target of $450, describing it as a juggernaut in artificial intelligence, leveraging its comprehensive portfolio of digital applications and cloud services to drive enterprise and consumer transformation, showcasing its strong market position.
- Algonquin Power Rating: Barclays initiates coverage of Algonquin Power & Utilities with an Overweight rating, citing the company's undervaluation and strong turnaround potential, indicating market confidence in its future performance.
See More
Private Sector Adds 62,000 Jobs in March, Exceeding Expectations
- Job Growth Overview: Private sector employment increased by 62,000 in March, down 4,000 from February's revised total of 66,000 but exceeding the Dow Jones estimate of 39,000, indicating resilience in economic recovery.
- Sector Contribution Analysis: The education and health services sector contributed 58,000 jobs, while construction added 30,000, highlighting the critical role of the health services industry in transforming the labor market.
- Small Business Dominance: Businesses with fewer than 50 employees added 85,000 jobs, while medium-sized firms lost 20,000, indicating a shift towards small businesses leading the recovery, potentially due to inflation impacts and the need for multiple jobs.
- Wage Growth Trends: Wage growth for those remaining in their jobs held steady at 4.5%, while job changers saw a 6.6% increase, up 0.3 percentage points from February, reflecting tightening competition in the labor market.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
Schwab U.S. Dividend Equity ETF Reconstitution Boosts Healthcare Allocation
- Annual Reconstitution Update: The Schwab U.S. Dividend Equity ETF has optimized its portfolio through the deletion of 22 stocks and the addition of 25 new stocks in its latest annual reconstitution, ensuring it holds the top 100 high-yield dividend stocks and enhancing overall portfolio quality.
- Increased Healthcare Allocation: Following the reconstitution, the allocation to the healthcare sector has risen from 15.4% to 18.9%, with UnitedHealth and Abbott Laboratories joining the top ten holdings at 4% and 3.95% respectively, thereby strengthening the fund's investment in the healthcare sector.
- Dividend Growth Potential: While the overall dividend yield of the ETF remains at 3.4% post-reconstitution, the new holdings boast a higher average five-year dividend growth rate of 9.4%, which is expected to generate greater long-term income for investors, enhancing the fund's appeal.
- Strong Dividend Track Record: Both UnitedHealth and Abbott Laboratories have impressive dividend growth records, with the former increasing dividends by 52% over the past five years and the latter by 40%, providing investors with a stable income source and further solidifying the ETF's investment value.
See More
